Tests a gut-made supplement, indole-3-propionic acid, in relapsing multiple sclerosis
Tests the dietary supplement indole-3-propionic acid against placebo in adults with relapsing multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Key facts
- Where
- Glostrup Municipality, DenmarkSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07318129, who can take part
Where in Denmark
- Glostrup HospitalGlostrup Municipality, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Glostrup University Hospital, Copenhagen
- Trial code
- NCT07318129
- Record updated
- 28 January 2026
- Original description
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.Read full original descriptionShow less
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Inclusion: Women and men ≥18 and ≤65 years of age; Diagnosed with RRMS according to the 2017 McDonald criteria (or newer updates); Routinely treated and monitored for MS; Speak and read Danish; Deemed physically and mentally able to participate in this study.
Exclusion: Haematopoietic stem cell transplantation; Current or past treatment with non-MS related treatments deemed to be relevant; Active malignancy; Diagnosis of Crohn's disease and ulcerative colitis; People with MR contraindications:; Severe claustrophobia; Incompatible implants/ foreign objects, including implanted pacemakers, heart valve prostheses, prostheses in the middle ear, implanted devices (e.g., insulin pump), metal debris, e.g., metal splinters in the eyes, miscellaneous shunts and catheters, metal clips from operations; Other comorbidities deemed to be relevant; Pregnancy or lactation.